Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Scheduled for atherosclerotic vascular elective surgery with presumed fast-track,~* Cardiac ischaemic risk supported by:~  * History of myocardial infarction older than 1 month and/or~ * Documented Stable angina (asymptomatic ± medical treatment) and/or~ * History of coronary revascularisation, and/or~ * Surgical Risk Index (Lee index) ≥ 3.~ * Written informed consent~Exclusion Criteria:~* Unstable angina within the last 30 days,~* Non controlled arterial Hypertension .~* Severe Cardiac heart Failure (NYHA IV)~* Severe Chronic Obstructive Pulmonary Disease~* Patient already randomized in another ongoing clinical trial~* Patient with recent myocardial infarction (M.I) (less than one month )~* Patient already included in a clinical trial~* History of hypersensitivity to study drugs( i.e Xenon, propofol, sevoflurane, desflurane, isoflurane)~* Malignant hyperthermia~* Documented Elevated intracranial pressure~* Preeclampsia or eclampsia~* Pregnancy and lactation~* Presumed uncooperativeness or legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xenon (Type: EXPERIMENTAL): 0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
- sevoflurane (Type: ACTIVE_COMPARATOR): 0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)

Based on this trial design, predict the completion outcome and termination type (if applicable).